Enoxaparin is made from heparin and is one type of the low molecular weight heparin (LMWH). It is used as an anticoagulant that prevents the formation of blood clots also known as ‘blood thinner’. It is used to treat various conditions including deep vein thrombosis (DVT), pulmonary embolism in the lungs, acute coronary syndrome and heart attack. An incidence rate of venous thromboembolism was observed around ~0.1% to 0.2% in the U. S. population. As per WHO classification, enoxaparin has listed under essential medicines and was considered as the most commonly prescribed medication in the U. S.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32054
In the COVID-19 pandemic, millions of the individual has been affected globally by COVID-19 infection. In significant severe cases, blood density/clot was one of the major observed complication. The national healthcare authorities has rendered advice to all medical and public healthcare faciltiies regarding the need of enoxaparin availability. The COVID-19 outbreak is expected to feul the growth of enoxaparin API market.
The rise in unmet global demand of the blood thinner drugs is expected to drvie the enoxaparin API market globally owing to increase in the prevalence of chronic and cardiovascular diseases. Availability of low molecular weight enoxaparin (LMWH) over unfractionated heparin is one of the major factor that is expected to propel the market growth over the forecast period. The rise in the price of enoxaparin API in China has a significant negative impact on the growth of market. Adverse effects associated with enoxaparin during treatment is expcted to hamper the growth of the enoxaparin API market. Strigent regulatory norms in the developed markets is expected to contract the growth of the enoxaparin API market.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32054
Globally, the enoxaparin API market is segmented based on dose strength, packaging, application, end user, and region.
| Based on molecular weight |
|
| Based on packaging |
|
| Based on indication |
|
| Based on end user |
|
| Based on the region |
|
High molecular weight of enoxaparin hold the major revenue share in the global enoxaparin API market. By packaging, multi vials segment leads the market share in the global enoxaparin API market. Multi vials packaing provide low cost alternative to a huge demand of the enoxaparin treatment. Pulmonary embolism dominate the global enoxaparin API market by the indication owing to high incidecne of the pulmonary embolism across the globe. COVID-19 is becoming a dominant disruptive factor in the global market as it has significantly surged the demand of the blood thinners across the world. Pharmaceutical manufacturers end user hold the major revenue share followed by the contract manufacturing organization in the global enoxaparin API market.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32054
Asia Pacific is dominating the market and is expected to increase over the next few years due to well-estblished state-of-art facilties in the region. North America and Europe is expected to second most opportunitstic market in the Enoxaparin API market owing to rise in the pharmcautical manufacturers in the region. Latin America is emerging and may expect to grow moderately in the future. Usage of enoxaparin in China is increasing in 2019 and is expected to increase more till 2025 that will propel the growth of market.
The key players operating in the enoxaparin API market are Shenzhen Hepalink Pharmaceutical Group, Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Bristol Myer Squibb Company, Bohehringer Ingelheim, Eisai Inc., Teva Pharmaceutical Industries Ltd., Abbot India Limited, Novartis AG, ChemWerth, Laboratorios Farmaceuticos ROVI SA, Gland Pharma Limited, Hanways Chempharma Co. Ltd, Changzhou Qianhong Biopharma, and others.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com